Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer

Published:2022-03-14 Issue:7 Volume:82 Page:858-866
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Zhang Tian¹²³^ORCID,Kephart Julie¹,Bronson Elizabeth¹,Anand Monika¹^ORCID,Daly Christine¹,Spasojevic Ivan²,Bakthavatsalam Subha⁴,Franz Katherine⁴,Berg Hannah¹,Karachaliou Georgia S.¹,James Olga G.⁵,Howard Lauren⁶,Halabi Susan⁶,Harrison Michael R.¹²,Armstrong Andrew J.¹²⁷⁸,George Daniel J.¹²⁷

Affiliation:

1. Duke Cancer Institute Center for Prostate and Urologic Cancers Duke University Durham North Carolina USA

2. Division of Medical Oncology, Department of Medicine Duke University Durham North Carolina USA

3. Division of Hematology and Oncology, Department of Internal Medicine UT Southwestern Medical Center Dallas Texas USA

4. Department of Chemistry Duke University Durham North Carolina USA

5. Division of Nuclear Medicine, Department of Radiology Duke University Durham North Carolina USA

6. Department of Biostatistics and Bioinformatics Duke University Durham North Carolina USA

7. Division of Urology, Department of Surgery Duke University Durham North Carolina USA

8. Department of Pharmacology and Cancer Biology Duke University Durham North Carolina USA

Funder

V Foundation for Cancer Research

Peter Michael Foundation

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24329

Reference26 articles.

1. Cancer Statistics, 2021

2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

4. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

5. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A cuproptosis-based nanomedicine suppresses triple negative breast cancers by regulating tumor microenvironment and eliminating cancer stem cells;Biomaterials;2025-02

2. S-(N,N-diethyldithiocarbamoyl)-N-acetyl- l -cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity;Journal of Drug Targeting;2024-07-12

3. Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis;International Immunopharmacology;2024-06

4. Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment;International Journal of Pharmaceutics: X;2024-06

5. ATPase Copper Transporting Beta (ATP7B) Is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer;Molecular Cancer Therapeutics;2024-02-28